A Phase 2, Multi-centeR, Randomized, DoUBle-Masked, Placebo-Controlled StudY to Evaluate the Clinical Safety and Efficacy of OKG-0301 in the Treatment of Acute Adenoviral Conjunctivitis (RUBY)
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Ranpirnase (Primary)
- Indications Viral-conjunctivitis
- Focus Adverse reactions
- Sponsors Okogen
- 25 Feb 2019 Status changed from planning to recruiting.
- 08 Mar 2018 New trial record
- 27 Feb 2018 According to an Okogen media release, the Company plans to initiate this trial before the end of 2018.